HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asselah, T Articles by Negro, F Search for Related Content PubMed PubMed Citation Articles by Asselah, T Articles by Negro, F Topic Collections Relevant Article

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

¹ Service d’Hépatologie and INSERM CRB3, Hôpital Beaujon, Clichy, France
² Service de Pathologie Clinique, Hôpital Universitaire, Genève, Switzerland
³ Services de Pathologie Clinique, de Gastroentérologie et d’Hépatologie, Hôpital Universitaire, Genève, Switzerland

Correspondence to:
Correspondence to:
Dr P Marcellin
Service d’Hépatologie and INSERM CRB3, Hôpital Beaujon, Clichy 92 110, France; patrick.marcellin@bjn.ap-hop-paris.fr

Keywords: fibrosis; insulin resistance; genotype; non-alcoholic steatohepatitis; treatment

The first 150 words of the full text of this article appear below.

SUMMARY
Hepatic steatosis is a common histological feature of chronic hepatitis C. Various factors are associated with hepatic steatosis, including obesity, high alcohol consumption, diabetes type II, and hyperlipidaemia. These factors may contribute to steatosis in patients with chronic hepatitis C. In humans, hepatitis C virus (HCV) genotype 3 is more commonly associated with steatosis. In vitro studies and the transgenic mouse model have suggested that the HCV core protein (genotype 1) can induce lipid accumulation within hepatocytes.

However, what is the relevance of steatosis in chronic hepatitis C? It seems that in certain populations, steatosis may be associated with fibrosis progression and this may be genotype specific. The mechanisms underlying this association are unknown; neither is it clear whether this holds true for all patients or only a subgroup. Indeed, after antiviral treatment, virus related steatosis disappears whereas the host associated steatosis remains unaffected.

This review describes and discusses the . . . [Full text of this article]

Relevant Article

Steatosis in chronic hepatitis C • Authors’ reply

M Guidi, P Muratori, A Granito, L Muratori, M Lenzi, F B Bianchi, T Asselah, L Rubbia-Brandt, P Marcellin, and F Negro
Gut 2006 55: 1047-1048. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J.-K. Oem, C. Jackel-Cram, Y.-P. Li, Y. Zhou, J. Zhong, H. Shimano, L. A. Babiuk, and Q. Liu Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2 J. Gen. Virol., May 1, 2008; 89(5): 1225 - 1230. [Abstract] [Full Text] [PDF]

				S. Banerjee, K. Saito, M. Ait-Goughoulte, K. Meyer, R. B. Ray, and R. Ray Hepatitis C Virus Core Protein Upregulates Serine Phosphorylation of Insulin Receptor Substrate-1 and Impairs the Downstream Akt/Protein Kinase B Signaling Pathway for Insulin Resistance J. Virol., March 15, 2008; 82(6): 2606 - 2612. [Abstract] [Full Text] [PDF]

				P Riley, J O'Donohue, and M Crook A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease J. Clin. Pathol., December 1, 2007; 60(12): 1384 - 1391. [Abstract] [Full Text] [PDF]

				C Hourioux, R Patient, A Morin, E Blanchard, A Moreau, S Trassard, B Giraudeau, and P Roingeard The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model Gut, September 1, 2007; 56(9): 1302 - 1308. [Abstract] [Full Text] [PDF]

				G. Waris, D. J. Felmlee, F. Negro, and A. Siddiqui Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress J. Virol., August 1, 2007; 81(15): 8122 - 8130. [Abstract] [Full Text] [PDF]

				L. Codes, T. Asselah, D. Cazals-Hatem, F. Tubach, D. Vidaud, R. Parana, P. Bedossa, D. Valla, and P. Marcellin Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy Gut, March 1, 2007; 56(3): 390 - 395. [Abstract] [Full Text] [PDF]

eLetters: